181 related articles for article (PubMed ID: 11192745)
21. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Campbell P
N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
[No Abstract] [Full Text] [Related]
22. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
24. What have We learned from ESPRIT? What will we learn from TARGET?
Ferguson JJ
J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
[No Abstract] [Full Text] [Related]
25. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Chesebro JH; Badimon JJ
N Engl J Med; 1998 May; 338(21):1539-41. PubMed ID: 9593795
[No Abstract] [Full Text] [Related]
26. Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Gibson CM; Goel M; Murphy SA; Dotani I; Marble SJ; Deckelbaum LI; Dodge JT; King SB;
Am J Cardiol; 2000 Dec; 86(12):1375-7, A5. PubMed ID: 11113417
[TBL] [Abstract][Full Text] [Related]
27. [Acute coronary syndromes without ST-elevation -- treatment].
Weber M; Hamm C
Dtsch Med Wochenschr; 2003 Feb; 128(6):273-6. PubMed ID: 12571797
[No Abstract] [Full Text] [Related]
28. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
[TBL] [Abstract][Full Text] [Related]
29. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
Feldmann C; Deutsch HJ
Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
[No Abstract] [Full Text] [Related]
30. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
Januzzi JL; Sabatine MS; Wan Y; Servoss SJ; DiBattiste PM; Jang Ik; Theroux P
Am J Cardiol; 2003 Feb; 91(4):457-61. PubMed ID: 12586266
[No Abstract] [Full Text] [Related]
31. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
32. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
33. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.
Cutlip DE; Ricciardi MJ; Ling FS; Carrozza JP; Dua V; Garringer J; Giri S; Caputo RP
Am J Cardiol; 2003 Oct; 92(8):977-80. PubMed ID: 14556878
[TBL] [Abstract][Full Text] [Related]
34. National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
Bakhai A; Flather MD; Collinson JR; Stevens W; Normand C; Alemao E; Itzler R; Ben-Joseph R
Int J Cardiol; 2003 Oct; 91(2-3):163-72. PubMed ID: 14559126
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
36. Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
Uyarel H; Uzunlar B; Unal Dayi S; Tartan Z; Samur H; Kasikcioglu H; Akgul O; Simsek D; Erdem I; Okmen E; Cam N
Cardiology; 2006; 105(3):168-75. PubMed ID: 16479104
[TBL] [Abstract][Full Text] [Related]
37. [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
Rasmussen S; Husted SE
Ugeskr Laeger; 2001 Jan; 163(4):461-5. PubMed ID: 11218789
[TBL] [Abstract][Full Text] [Related]
38. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
39. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
Brener SJ
J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
[No Abstract] [Full Text] [Related]
40. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Weintraub WS; Culler S; Boccuzzi SJ; Cook JR; Kosinski AS; Cohen DJ; Burnette J
J Am Coll Cardiol; 1999 Oct; 34(4):1061-6. PubMed ID: 10520791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
